feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouUnited StatesUnited States
You
bookmarksYour BookmarkshashtagYour Topics
Trending
trending

Taipei mass stabbing kills four

trending

Rhode Island energy outage

trending

YouTube and Google faced outages

trending

Luke Air Force Base shooting

trending

Metro Detroit school closings Friday

trending

Target app outage reported

trending

Colorado power shutoffs evaluated

trending

Slippery road conditions expected

trending

Rocket Lab stock surges

Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2025 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / Miracle Cancer Survivor Glenda Drake's Second Chance

Miracle Cancer Survivor Glenda Drake's Second Chance

19 Dec

•

Summary

  • Glenda Drake, once facing terminal cancer, is now cancer-free.
  • Revolutionary immunotherapy treatment played a key role in her recovery.
  • Her inspiring journey offers hope and encourages medical innovation.
Miracle Cancer Survivor Glenda Drake's Second Chance

Glenda Drake is embracing a new lease on life, celebrating seven months cancer-free after a near-fatal diagnosis. Initially given a grim prognosis for a high-grade Neuroendocrine tumor in October 2023, Drake's condition was advanced and aggressive. Her medical team, led by Dr. Omer Ilyas at the Community Cancer Institute in Clovis, pursued a novel treatment approach.

Dr. Ilyas incorporated immunotherapy alongside traditional chemotherapy and radiation, a decision spurred by the discovery of an MSI High status in her tumor. This innovative strategy, though not yielding immediate results, ultimately allowed Drake's immune system to combat the cancer. By October 2024, she had entered hospice care, surrounded by family, but a surprising turn of events saw her health improve significantly.

Drake's miraculous recovery is a testament to perseverance and medical advancement. Her story inspires hope, encouraging both patients and medical professionals to explore new treatment options and never give up. She now cherishes every moment, appreciating her loved ones and advocating for thorough testing before dismissing potential therapies like immunotherapy.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
Glenda Drake beat aggressive cancer through a combination of chemotherapy, radiation, and a novel immunotherapy treatment.
The Community Cancer Institute in Clovis is known for its work with advanced cancer treatments, including immunotherapy.
Immunotherapy can be effective for some high-grade Neuroendocrine tumors, particularly those with an MSI High status, as seen in Glenda Drake's case.

Read more news on

Healthside-arrow

You may also like

UK Partnership Turns Uranium into Cancer Drugs

16 Dec • 19 reads

article image

Hina Khan's Brave Battle With Stage 3 Breast Cancer

13 Dec • 42 reads

article image

King Charles' Cancer Fight: Precautionary Treatment Ahead

13 Dec • 50 reads

article image

Summit's Cancer Drug Rivals Keytruda

10 Dec • 62 reads

article image

Stage IV Cancer Patient Transforms Radiation Mask into Art

6 Dec • 68 reads

article image